Feature | October 15, 2014

Veterinary CyberKnife Cancer Center Opens Advanced Radiation Treatment Center for Pets in Malvern, Pa.

Veterinarians can now treat tumors not historically treated with radiation

October 15, 2014 — Veterinary CyberKnife Cancer Center (VC3), a privately owned advanced radiation treatment center for veterinary use, today announced the opening of its facility in Malvern, Pa. The CyberKnife is a non-invasive way to deliver radiation to tumors, enabling treatment with greater precision than traditional linear accelerators and intensity modulated radiation therapy (IMRT) machines. The CyberKnife delivers an entire therapeutic dose of radiation in one to three treatments versus 17 to 20 treatments of traditional radiation therapy. VC3 has changed the way companion animals with cancerous tumors are treated.

CyberKnife (manufactured by Accuray Inc. of Sunnyvale, Calif.), is also called stereotactic radiosurgery. It utilizes a sophisticated robotic arm that revolves around the animal, delivering precisely targeted radiation to the tumor while sparing healthy tissue and surrounding organs. The precision of the CyberKnife allows tumors that haven’t historically been treated with radiation in the veterinary field, such as lung and liver tumors, to be treated. The end result is more precise and far fewer treatments, a significantly reduced number of anesthetic episodes, fewer visits to the veterinarian and a better quality of life for the pet and owner.

“The CyberKnife offers the best clinical option for the majority of my patients undergoing palliative or definitive radiation treatment,” said Siobhan Haney, DVM., M.S., DACVR (RO), MBA. Haney is a veterinary radiation oncologist at Hope Veterinary Specialists in Malvern, Pa.

VC3 owns and operates one of only two CyberKnifes in the world devoted for veterinary use and the only CyberKnife for veterinary use in the Mid-Atlantic region.

For more information: www.vetcyberknife.com


Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at
Improved Imaging for Prostate Cancer Could Lead to More Effective Treatment

The picture shows that time series signal is extracted from a series of ultrasound frames for classification. Each patch across a number of frames inside the prostate is classified into either cancerous or normal tissue. The image at the lower right corner shows the overall result for those frames. Image courtesy of Pingkun Yan and researchers from NIH, University of British Columbia and Queens University.

News | Ultrasound Imaging | May 28, 2019
Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more...